"Pharma Bro" Martin Shkreli Really Upped His Weirdo Villain Game This Week

"Pharma Bro" Martin Shkreli, the CEO of Turing Pharmaceuticals, has been America's favorite corporate villain lately. On Sept. 21, 2015, public ire for the young biopharma exec surfaced after he purchased the rights to the drug Daraprim and skyrocketed the price to $750 overnight. Public relations in the weeks since for the young exec have only gotten worse... Tags: Bernie Sanders Martin Shkreli , CEO Martin Shkreli , Daraprim , Imprimis , Mark L. Baum , Martin Shkreli , Martin Shkreli Bernie Sanders , martin shkreli bernie sanders donation , Nasdaq: IMMY , pharma bro , pharma bro Martin Shkreli , Shkreli , Turing Pharmaceuticals To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post "Pharma Bro" Martin Shkreli Really Upped His Weirdo Villain Game This Week appeared first on Money Morning - We Make Investing Profitable .